Prothena (PRTA) AI Stock Analysis

• Market Cap: $537.76M
• Dividend Yield: N/A
• Average Volume (3M): 732.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: -91.16%
• EPS Growth: -112.24%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.68
• Shares Outstanding: 53,829,983
• 10 Day Avg. Volume: 686,318
• 30 Day Avg. Volume: 732,465
• PEG Ratio: 0.34
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 5.51
• P/FCF Ratio: -4.95
• Enterprise Value/Market Cap: -0.06
• Enterprise Value/Revenue: -2.96
• Enterprise Value/Gross Profit: 2.04
• Enterprise Value/Ebitda: 0.16
• 1Y Price Target: $21.20
• Price Target Upside: 112.21% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $11.00 ▲(10.11% Upside)

Prothena's overall stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flows. Technical analysis shows positive momentum, but valuation metrics are weak due to ongoing losses. The absence of recent earnings commentary adds uncertainty.

Positive Factors

Strategic Partnerships

Prothena's partnerships with major pharmaceutical companies like Novo Nordisk enhance its financial resources and market reach, providing a durable competitive advantage in drug development and commercialization.

Pipeline Development

Advancement of late-stage clinical programs, such as the Phase 3 trials, indicates strong pipeline development, which is crucial for long-term growth and potential future revenue streams.

Regulatory Advancements

Fast Track designation for BMS-986446 by the FDA accelerates the development process, potentially bringing treatments to market faster, enhancing Prothena's strategic position in the biotech industry.

Negative Factors

Negative Cash Flow

Persistent negative cash flows indicate potential liquidity issues, limiting Prothena's ability to fund operations and growth without external financing, which could impact its long-term financial health.

Profitability Challenges

Ongoing profitability challenges suggest difficulty in achieving sustainable earnings, which could hinder Prothena's ability to reinvest in R&D and maintain competitive positioning.

Revenue Decline

Significant revenue shortfall against expectations highlights potential issues in revenue generation, which could affect Prothena's ability to fund future projects and maintain investor confidence.

Prothena Business Overview & Revenue Model

Company Description

Prothena Corporation plc is a clinical-stage biotechnology company focused on the discovery and development of therapies for diseases involving protein misfolding and aggregation, with a primary emphasis on neurodegenerative diseases. The company's core products include monoclonal antibodies and other therapeutic candidates designed to target and modify the underlying biology of these conditions. Prothena operates in the biotechnology sector and is dedicated to advancing innovative approaches to treat diseases such as Alzheimer's and Parkinson's.

How the Company Makes Money

Prothena generates revenue primarily through collaborations and partnerships with pharmaceutical companies, which often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on sales of approved products. The company may also receive funding from government grants and research institutions for specific projects. Prothena's strategic alliances with larger pharmaceutical firms can significantly enhance its financial resources and provide access to broader distribution networks, thereby contributing to its overall earnings. Additionally, any successful commercialization of its therapeutic candidates can lead to substantial revenues from product sales and licensing agreements.

Prothena Financial Statement Overview

Summary

Prothena faces significant financial challenges, with declining revenue, negative profit margins, and cash flow difficulties. Despite a low debt-to-equity ratio indicating limited leverage, the company struggles with profitability and cash flow issues, which are critical for its financial health.

Income Statement

Prothena's income statement reveals significant challenges, with declining revenue and negative profit margins. The TTM data shows a sharp revenue decline of over 92%, and the net profit margin is deeply negative at -29.29%. The company has struggled with profitability, as evidenced by negative EBIT and EBITDA margins. Despite past revenue growth, recent trends indicate financial instability.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.03, indicating limited leverage and potential financial stability. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is not provided, but the company's equity position appears relatively strong compared to its debt, which is a positive aspect.

Cash Flow

Cash flow analysis indicates negative operating and free cash flows, with a slight improvement in free cash flow growth. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. The free cash flow to net income ratio is close to 1, suggesting that cash flow issues are aligned with net income losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.79M	135.16M	91.37M	53.91M	200.58M	853.00K
Gross Profit	-17.15M	135.16M	91.37M	53.91M	200.58M	-74.03M
EBITDA	-217.76M	-153.67M	-190.11M	-130.81M	73.09M	-111.22M
Net Income	-280.46M	-122.31M	-147.03M	-116.95M	66.97M	-111.14M
Balance Sheet
Total Assets	352.63M	547.11M	696.38M	758.03M	609.37M	332.98M
Cash, Cash Equivalents and Short-Term Investments	330.84M	471.39M	618.83M	710.41M	579.09M	295.38M
Total Debt	9.08M	10.84M	11.84M	6.47M	12.33M	17.84M
Total Liabilities	57.64M	60.18M	135.02M	135.99M	143.32M	148.97M
Stockholders Equity	294.99M	486.93M	561.37M	622.04M	466.04M	184.01M
Cash Flow
Free Cash Flow	-188.22M	-150.35M	-136.72M	-109.28M	92.03M	-80.56M
Operating Cash Flow	-188.04M	-150.05M	-133.91M	-108.82M	92.61M	-80.36M
Investing Cash Flow	-181.00K	-298.00K	-2.77M	-464.00K	-575.00K	-196.00K
Financing Cash Flow	-198.00K	1.55M	45.10M	241.46M	190.33M	215.00K

Prothena Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTA, the sentiment is Neutral. The current price of 9.99 is below the 20-day moving average (MA) of 10.33, above the 50-day MA of 9.81, and above the 200-day MA of 9.31, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 47.24 is Neutral, neither overbought nor oversold. The STOCH value of 35.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRTA.

Prothena Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZVRA	61 Neutral	$544.96M	15.35	34.81%	―	240.47%	―
PRTA	52 Neutral	$537.76M	-1.92	-67.63%	―	-91.16%	-112.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LXRX	51 Neutral	$483.32M	-3.99	-45.92%	―	1255.21%	74.58%
XOMA	51 Neutral	$392.73M	-21.06	16.22%	―	118.02%	―
ALMS	43 Neutral	$574.43M	―	-66.88%	―	―	13.80%
CRVS	41 Neutral	$665.42M	―	-35.82%	―	―	79.27%

Prothena Corporate Events

Prothena Corporation’s Q3 2025 Financial and Clinical Updates

Prothena Corporation is a late-stage clinical biotechnology company focusing on investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, leveraging its expertise in protein dysregulation.

Prothena Announces Promising Phase 1 Results for PRX012

On August 27, 2025, Prothena announced results from its Phase 1 ASCENT clinical program for the investigational drug PRX012, aimed at treating early symptomatic Alzheimer’s disease. The study demonstrated that PRX012, a once-monthly, subcutaneous anti-amyloid beta antibody, showed promising results in reducing amyloid plaque but had higher ARIA-E rates compared to FDA-approved antibodies. Prothena plans to seek partnerships to further develop PRX012 and its preclinical PRX012-TfR antibody, which may offer a reduced risk of ARIA and quicker amyloid plaque reduction.

The most recent analyst rating on (PRTA) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.